Ardelyx Announces Departure of Board Member
13 Noviembre 2023 - 3:02PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that Geoffrey Block, MD, is stepping down from the
Board of Directors after nearly five years of service. Dr. Block
currently serves as the Associate Chief Medical Director and Senior
Vice President of Clinical Research and Medical Affairs at U.S.
Renal Care.
“On behalf of our board and Ardelyx’s leadership
team, we thank Geoff for his unwavering commitment and the
instrumental role he played in helping guide and evolve Ardelyx
from a developmental, clinical-stage biopharmaceutical company to
an established commercial entity,” said David Mott, Chair of the
Ardelyx Board of Directors. “It has been a pleasure working with
Geoff, and I would personally like to thank him for his ongoing
support.”
“I am very proud of this leadership team’s many
accomplishments and am grateful for the opportunity to have served
on the board of directors,” said Dr. Block. “Ardelyx is
well-positioned for the future, following the U.S. FDA approval of
the first-in-class phosphate absorption inhibitor XPHOZAH®
(tenapanor) which is a new option for the many patients with
chronic kidney disease on dialysis, a community I have dedicated my
career to serving. The time is right for me step down from the
board of directors as Ardelyx embarks on its next phase.”
About Ardelyx, Inc.Ardelyx was
founded with a mission to discover, develop and commercialize
innovative, first-in-class medicines that meet significant unmet
medical needs. Ardelyx has two commercial products approved in the
United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as
well as early-stage pipeline candidates. Ardelyx has agreements for
the development and commercialization of tenapanor outside of the
U.S. Kyowa Kirin has received approval for PHOZEVEL® (tenapanor)
for hyperphosphatemia in Japan. A New Drug Application for
tenapanor for hyperphosphatemia has been submitted in China with
Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada.
For more information, please visit https://ardelyx.com/ and connect
with us on X (formerly known as Twitter), LinkedIn and
Facebook.
Investor and Media Contacts:
Caitlin Lowieclowie@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ardelyx (NASDAQ:ARDX)
Gráfica de Acción Histórica
De May 2023 a May 2024